GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (BOM:500674) » Definitions » Price-to-Owner-Earnings

Sanofi India (BOM:500674) Price-to-Owner-Earnings : 77.02 (As of May. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Sanofi India Price-to-Owner-Earnings?

As of today (2024-05-27), Sanofi India's share price is ₹8832.75. Sanofi India's Owner Earnings per Share (TTM) ended in Dec. 2023 was ₹114.68. It's Price-to-Owner-Earnings for today is 77.02.


The historical rank and industry rank for Sanofi India's Price-to-Owner-Earnings or its related term are showing as below:

BOM:500674' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.57   Med: 36.1   Max: 79.64
Current: 77.02

During the past 13 years, the highest Price-to-Owner-Earnings of Sanofi India was 79.64. The lowest was 15.57. And the median was 36.10.


BOM:500674's Price-to-Owner-Earnings is ranked worse than
84.45% of 418 companies
in the Drug Manufacturers industry
Industry Median: 27.325 vs BOM:500674: 77.02

As of today (2024-05-27), Sanofi India's share price is ₹8832.75. Sanofi India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹261.78. Therefore, Sanofi India's PE Ratio for today is 33.74.

As of today (2024-05-27), Sanofi India's share price is ₹8832.75. Sanofi India's EPS without NRI for the trailing twelve months (TTM) ended in was ₹256.96. Therefore, Sanofi India's PE Ratio without NRI for today is 34.37.

During the past 13 years, Sanofi India's highest PE Ratio without NRI was 50.06. The lowest was 23.14. And the median was 33.40.


Sanofi India Price-to-Owner-Earnings Historical Data

The historical data trend for Sanofi India's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India Price-to-Owner-Earnings Chart

Sanofi India Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.08 32.27 17.30 22.77 70.34

Sanofi India Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.77 - - - 70.34

Competitive Comparison of Sanofi India's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Sanofi India's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi India's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi India's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sanofi India's Price-to-Owner-Earnings falls into.



Sanofi India Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sanofi India's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=8832.75/114.68
=77.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi India  (BOM:500674) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sanofi India Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sanofi India's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi India (BOM:500674) Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospital, Central Nervous System, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth strategy.

Sanofi India (BOM:500674) Headlines

No Headlines